Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive <scp>AMPA</scp> receptor antagonist perampanel

Abstract

Patients and caregivers should be counseled regarding the potential risk of psychiatric and behavioral events with perampanel in patients with partial seizures; patients should be monitored for these events during treatment, especially during titration and at higher doses.